Novo Nordisk stock loses 0.47 percent pre-market to EUR 33.86
Published on 10/09/2026 at 07:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Novo Nordisk stock is down 0.47 percent pre-market at EUR 33.86.
- Novo Nordisk is scheduled to report first-three-quarter results on November 4, 2026.
- HSBC raised its target to DKK 320.00 and reiterated a hold rating.
Novo Nordisk stock is at EUR 33.86 in pre-market trading at Lang & Schwarz at 7:41 a.m. CEST on October 9, 2026, down 0.47 percent versus the prior close of EUR 34.02 on October 8, 2026.
Pre-market indication
The Lang & Schwarz bid was EUR 33.82 and the ask was EUR 33.90. Novo Nordisk A/S is listed as NOVO B on Nasdaq Copenhagen. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Novo Nordisk stock.
What matters today. Novo Nordisk’s next scheduled financial-results date is November 4, 2026, at 7:30 a.m. CEST, when it will announce results for the first three quarters of 2026. A round-number level of EUR 35.00 is 3.37 percent above the EUR 33.86 pre-market price. HSBC’s most recent target was DKK 320.00 on September 10, 2026, raised from DKK 300.00, with a hold rating.
Scheduled results and analyst target
Novo Nordisk lists the November 4 announcement in its financial-results calendar and says full-year 2026 results will be announced before the opening of the Nasdaq Copenhagen stock exchange. Separately, Marketscreener reported that HSBC raised its target to DKK 320.00 from DKK 300.00 and maintained a hold rating.
Market context: Latest market reports.
